The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 15, 2019
Filed:
Mar. 22, 2017
Applicant:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Bing-Yan Zhu, Palo Alto, CA (US);
Wenrong Huang, Cupertino, CA (US);
Assignee:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07D 213/81 (2006.01); A61K 31/44 (2006.01); C07C 237/42 (2006.01); C07C 255/60 (2006.01); C07C 257/18 (2006.01); C07C 259/18 (2006.01); C07C 311/16 (2006.01); C07C 311/46 (2006.01); C07C 317/40 (2006.01); C07C 317/44 (2006.01); C07D 213/75 (2006.01); C07D 213/82 (2006.01); C07D 217/22 (2006.01); C07D 231/12 (2006.01); C07D 233/56 (2006.01); C07D 233/64 (2006.01); C07D 249/08 (2006.01); C07D 295/125 (2006.01); C07D 333/38 (2006.01); C07D 401/12 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); A61K 31/616 (2006.01); A61K 45/06 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/44 (2013.01); A61K 9/20 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/48 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/616 (2013.01); A61K 45/06 (2013.01); C07C 237/42 (2013.01); C07C 255/60 (2013.01); C07C 257/18 (2013.01); C07C 259/18 (2013.01); C07C 311/16 (2013.01); C07C 311/46 (2013.01); C07C 317/40 (2013.01); C07C 317/44 (2013.01); C07D 213/75 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 217/22 (2013.01); C07D 231/12 (2013.01); C07D 233/56 (2013.01); C07D 233/64 (2013.01); C07D 249/08 (2013.01); C07D 295/125 (2013.01); C07D 333/38 (2013.01); C07D 401/12 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); A61K 2201/094 (2013.01);
Abstract
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.